Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis

Key Points

• This research aims to compare the risk of severe infection in multiple sclerosis patients treated with diroximel fumarate versus anti-CD20 monoclonal antibodies.
• Conducted a real-world claims analysis of adult multiple sclerosis patients
• Compared outcomes between diroximel fumarate and anti-CD20 treatments
• Analyzed risk of severe infection and annualized relapse rate
• DRF-treated patients showed a significantly lower risk of severe infection compared to anti-CD20 treated patients
• No difference was observed in the annualized relapse rate between the two treatments